Evidence map›Paper›PMID 35983595›Full record

ArticleIET systems biology2022

CHAC1 as a novel biomarker for distinguishing alopecia from other dermatological diseases and determining its severity.

Hassan Karami, Samira Nomiri, Mohammad Ghasemigol, Niloufar Mehrvarzian, Afshin Derakhshani, Mohammad Fereidouni, Masoud Mirimoghaddam, Hossein Safarpour

Open access · goldAbstract read
In one paragraph

Article in IET systems biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Hassan KaramiStudent Research Committee, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Samira NomiriDepartment of Biochemistry, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Mohammad GhasemigolDepartment of Computer Engineering, University of Birjand, Birjand, Iran.
Niloufar MehrvarzianDepartment of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Afshin DerakhshaniMcCaig Institute, Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada.
Mohammad FereidouniCellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Masoud MirimoghaddamDepartment of Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Hossein SafarpourCellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.ORCID 0000-0001-9883-9186
Birjand University of Medical Sciences · IRAllen Institute for Brain Science · USMashhad University of Medical Sciences · IRUniversity of Alberta · CAUniversity of Birjand · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alopecia Areata (AA) is characterised by an autoimmune response to hair follicles (HFs) and its exact pathobiology remains unclear. The current study aims to look into the molecular changes in the skin of AA patients as well as the potential underlying molecular mechanisms of AA in order to identify potential candidates for early detection and treatment of AA. We applied Weighted Gene Co-expression Network Analysis (WGCNA) to identify key modules, hub genes, and mRNA-miRNA regulatory networks associated with AA. Furthermore, Chi2 as a machine-learning algorithm was used to compute the gene importance in AA. Finally, drug-target construction revealed the potential of repositioning drugs for the treatment of AA. Our analysis using four AA data sets established a network strongly correlated to AA pathogenicity based on GZMA, OXCT2, HOXC13, KRT40, COMP, CHAC1, and KRT83 hub genes. Interestingly, machine learning introduced these genes as important in AA pathogenicity. Besides that, using another ten data sets, we showed that CHAC1 could clearly distinguish AA from similar clinical phenotypes, such as scarring alopecia due to psoriasis. Also, two FDA-approved drug candidates and 30 experimentally validated miRNAs were identified that affected the co-expression network. Using transcriptome analysis, suggested CHAC1 as a potential diagnostic predictor to diagnose AA.

Indexed as

Alopecia AreataMicroRNAsBiomarkersGene Expression ProfilingHumansBiomarkersMicroRNAsalopecia areatadrug repositioningmachine learningmolecular pathogenicitytranscriptome analysisWGCNA

Identifiers

PMID35983595
PMCPMC9469792
OpenAlexW4292493928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.